为了正常的体验网站,请在浏览器设置里面开启Javascript功能!

WHO CPP药品证明书-参考格式

2018-11-25 5页 doc 22KB 86阅读

用户头像

is_471618

暂无简介

举报
WHO CPP药品证明书-参考格式Model certificate of a pharmaceutical product Please refer to the guidelines for full instructions on how to complete this form and information on the implementation of the Scheme. The forms are suitable for generation by computer. They should always be submitted a...
WHO CPP药品证明书-参考格式
Model certificate of a pharmaceutical product Please refer to the guidelines for full instructions on how to complete this form and information on the implementation of the Scheme. The forms are suitable for generation by computer. They should always be submitted as hard copy, with responses printed in type rather than handwritten. Additional sheets should be appended, as necessary, to accommodate remarks and explanations. Certificate of a pharmaceutical product1 This certificate conforms to the format recommended by the World Health Organization No. of certificate Exporting (certifying country): Importing (requesting country): 1. Name and dosage form of the product: 1.1. Active ingredient(s)2 and amount(s) per unit dose3: For complete composition including excipients, see attached4: 1.2. Is this product licensed to be placed on the market for use in the exporting country?5 (yes/no) 1.3 Is this product actually on the market in the exporting country? If the answer to 1.2. is yes, continue with section 2A and omit section 2B. If the answer to 1.2 is no, omit section 2A and continue with section 2B6: 2.A.1. Number of product licence7 and date of issue: 2.A.2. Product licence holder (name and address): 2.A.3. Status of product licence holder8: (Key in appropriate category as defined in note 8) 2.A.3.1. For categories b and c the name and address of the manufacturer producing the dosage form is9: 2.A.4. Is a summary basis for approval appended?10 (yes/no) 2.A.5. Is the attached, officially approved product information complete and consonent with the licence?11 (yes/no/not provided) 2.A.6. Applicant for certificate, if different from licence holder (name and address)12: 2.B.1. Applicant for certificate (name and address): 2.B.2. Status of applicant: (Key in appropriate category as defined in footnote 8) 2.B.2.1. For categories (b) and (c) the name and address of the manufacturer producing the dosage form is:9 2.B.3. Why is marketing authorization lacking? (not required/not requested/under consideration/refused) 2.B.4. Remarks13: 3. Does the certifying authority arrange for periodic inspection of the manufacturing plant in which the dosage form is produced? (yes/no/not applicable)14 If not or not applicable, proceed to question 4. 3.1. Periodicity of routine inspections (years): 3.2. Has the manufacture of this type of dosage form been inspected? (yes/no) 3.3 Do the facilities and operations conform to GMP as recommended by the World Health Organization?15 (yes/no/not applicable)14 4. Does the information submitted by the applicant satisfy the certifying authority on all aspects of the manufacture of the product16: (yes/no) If no, explain: Address of certifying authority: Telephone: Fax: Name of authorized person: Signature Stamp and date Explanatory notes 1. This certificate, which is in the format recommended by WHO, establishes the status of the pharmaceutical product and of the applicant for the certificate in the exporting country. It is for a single product only since manufacturing arrangements and approved information for different dosage forms and different strengths can vary. 2. Use, whenever possible, International Nonproprietary Names (INNs) or national nonproprietary names. 3. The formula (complete composition) of the dosage form should be given on the certificate or be appended. 4. Details of quantitative composition are preferred but their provision is subject to the agreement of the product-licence holder. 5. When applicable, append details of any restriction applied to the sale, distribution or administration of the product that is specified in the product licence. 6. Sections 2A and 2B are mutually exclusive. 7. Indicate, when applicable, if the licence is provisional, or the product has not yet been approved. 8. Specify whether the person responsible for placing the product on the market: a. manufactures the dosage form; b. packages and/or labels a dosage form manufactured by an independent company; or c. is involved in none of the above. 9. This information can only be provided with the consent of the product-licence holder or, in the case of non-registered products, the applicant. Non-completion of this section indicates that the party concerned has not agreed to inclusion of this information. It should be noted that information concerning the site of production is part of the product licence. If the production site is changed, the licence has to be updated or it is no longer valid.
/
本文档为【WHO CPP药品证明书-参考格式】,请使用软件OFFICE或WPS软件打开。作品中的文字与图均可以修改和编辑, 图片更改请在作品中右键图片并更换,文字修改请直接点击文字进行修改,也可以新增和删除文档中的内容。
[版权声明] 本站所有资料为用户分享产生,若发现您的权利被侵害,请联系客服邮件isharekefu@iask.cn,我们尽快处理。 本作品所展示的图片、画像、字体、音乐的版权可能需版权方额外授权,请谨慎使用。 网站提供的党政主题相关内容(国旗、国徽、党徽..)目的在于配合国家政策宣传,仅限个人学习分享使用,禁止用于任何广告和商用目的。

历史搜索

    清空历史搜索